Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry - 09/12/21

Haley B. Naik, MD, MHSc ^{a, ⁎} , Raed Alhusayen, MBBS, MSCE, FAAD ^b, John Frew, MBBS, MMed, MSc, FACD ^c, Sandra Guilbault, BS ^d, Nancy K. Hills, PhD ^e, John R. Ingram, MRCP, MSc, FRCP ^f, Margaret V. Kudlinski, BS ^a, Michelle A. Lowes, MBBS, PhD, FACD ^g, Angelo Valerio Marzano, MD ^{h, i}, Maia Paul, MPH ^a, Bente Villumsen, MSc ^j, Christine A. Yannuzzi, BA ^k

^a Department of Dermatology, University of California, San Francisco, California 

^b Dermatology Division, Department of Medicine, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada 

^c Department of Dermatology, Liverpool Hospital, University of New South Wales, Sydney, Australia 

^d Hope for HS, Troy, Michigan 

^e Department of Neurology, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 

^f Division of Infection and Immunity, Department of Dermatology & Academic Wound Healing, Cardiff University, Cardiff, United Kingdom 

^g The Rockefeller University, New York, New York 

^h Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 

ⁱ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy 

^j Patientforeningen HS Danmark, Copenhagen, Denmark 

^k HS Warriors, Port Richey, Florida 

^∗Correspondence to: Haley B. Naik, MD, MHSc, Department of Dermatology, University of California, 1701 Divisadero St., Fourth Floor, San Francisco, CA 94115Department of DermatologyUniversity of California1701 Divisadero St.Fourth FloorSan FranciscoCA94115